A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (ADhere-J)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must be an adult or adolescent (12 to <18years) and weighing 40 kilogram (kg)
Participants must have atopic dermatitis that has been present for at least one year
Participants must have 10% body surface area (BSA) of atopic dermatitis involvement
Participants must have had an inadequate response to topical medications (medications applied to the skin)
Participants Must Not:
Participants must not have received a vaccine within 12 weeks of starting the study
Participants must not have hepatitis
Participants must not have a history of HIV
Participants must not have a history of cancer within 5 years
Female participants must not be pregnant, breastfeeding or plan to become pregnant during the study
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo